Amyloid oligomers: Formation and toxicity of Aβ oligomers

FEBS Journal

Volumn 277, Issue 6, 2010, Pages 1348-1358

  Sakono, Masafumi ^a,b   Zako, Tamotsu ^a  

^a RIKEN   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Alzheimer's disease; Amyloid ; Formation and toxicity mechanism; Intracellular and extracellular oligomers; Soluble amyloid oligomers

Indexed keywords

AMYLOID BETA PROTEIN; OLIGOMER;

ALZHEIMER DISEASE; BIOACCUMULATION; EXTRACELLULAR SPACE; MOLECULAR SIZE; MOLECULAR WEIGHT; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN POLYMORPHISM; SENILE PLAQUE; SHORT SURVEY; SYNAPSE;

AMYLOID BETA-PROTEIN; HUMANS; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; NEURODEGENERATIVE DISEASES; SOLUBILITY;

EID: 77749308402     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07568.x     Document Type: Short Survey

References (83)

1. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741 766.
2. Hardy JA Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184 185.
3. Terry RD, Maslia E Hansen LA (1999) The neuropathology of Alzheimer disease and the structural basis of its cogninitve alterations. In Alzheimer Disease (Terry RD, Katzman R, Bick KL Sisodia SS eds pp 187 206. Lipponcott Williams and Wilikins, Philadelphia.
4. Caughey B Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267 298.
5. Haass C Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101 112.
6. Laferla FM, Green KN Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499 509.
7. Klein WL, Krafft GA Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24, 219 224.
8. Chiti F Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75, 333 366.
9. Ferreira ST, Vieira MN De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59, 332 345.
10. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283, 29639 29643.
11. Roychaudhuri R, Yang M, Hoshi MM Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284, 4749 4753.
12. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 6448 6453.
13. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352 357.
14. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535 539.
15. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA et al. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133 140.
16. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB Selkoe DJ (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270, 9564 9570.
17. Walsh DM, Tseng BP, Rydel RE, Podlisny MB Selkoe DJ (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831 10839.
18. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea J-E, Ruotolo BT, Robinson CV et al. (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1, 326 331.
19. Ono K, Condron MM Teplow DB (2009) Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106, 14745 14750.
20. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103, 5161 5166.
21. Lefterov I, Fitz NF, Cronican A, Lefterov P, Staufenbiel M Koldamova R (2009) Memory deficits in APP23/Abca1+/- mice correlate with the level of Abeta oligomers. ASN Neuro 1, e00006.
22. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271, 4077 4081.
23. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA Holzman TF (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67, 1216 1228.
24. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE Klein WL (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79, 595 605.
25. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB Teplow DB (2003) Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 100, 330 335. Epub 2002 Dec 2027.
26. Lashuel HA Lansbury PT Jr. (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39, 167 201.
27. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N Sato K (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci USA 100, 6370 6375.
28. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486 489.
29. Necula M, Kayed R, Milton S Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282, 10311 10324.
30. Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P Smith SO (2006) High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 358, 106 119.
31. Losic D, Martin LL, Mechler A, Aguilar MI Small DH (2006) High resolution scanning tunnelling microscopy of the beta-amyloid protein (Abeta1-40) of Alzheimer's disease suggests a novel mechanism of oligomer assembly. J Struct Biol 155, 104 110.
32. Ding H, Wong PT, Lee EL, Gafni A Steel DG (2009) Determination of the oligomer size of amyloidogenic protein beta-amyloid(1-40) by single-molecule spectroscopy. Biophys J 97, 912 921.
33. Dukes KD, Rodenberg CF Lammi RK (2008) Monitoring the earliest amyloid-beta oligomers via quantized photobleaching of dye-labeled peptides. Anal Biochem 382, 29 34.
34. Garai K, Sengupta P, Sahoo B Maiti S (2006) Selective destabilization of soluble amyloid beta oligomers by divalent metal ions. Biochem Biophys Res Commun 345, 210 215.
35. Orte A, Birkett NR, Clarke RW, Devlin GL, Dobson CM Klenerman D (2008) Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc Natl Acad Sci USA 105, 14424 14429.
36. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M Yanagisawa K (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282, 2646 2655.
37. Yanagisawa K (2007) Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta 1768, 1943 1951.
38. Stege GJ, Renkawek K, Overkamp PS, Verschuure P, van Rijk AF, Reijnen-Aalbers A, Boelens WC, Bosman GJ de Jong WW (1999) The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem Biophys Res Commun 262, 152 156.
39. Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136, 22 31.
40. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P et al. (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 12749 12760.
41. Coulson EJ (2006) Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? J Neurochem 98, 654 660.
42. Dechant G Barde YA (2002) The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci 5, 1131 1136.
43. Costantini C, Della-Bianca V, Formaggio E, Chiamulera C, Montresor A Rossi F (2005) The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of beta-amyloid. Exp Cell Res 311, 126 134.
44. Zhang Y, Hong Y, Bounhar Y, Blacker M, Roucou X, Tounekti O, Vereker E, Bowers WJ, Federoff HJ, Goodyer CG et al. (2003) p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 23, 7385 7394.
45. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590 11601.
46. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 2866 2875.
47. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST Klein WL (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 106, 1971 1976.
48. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246 260.
49. Townsend M, Mehta T Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282, 33305 33312.
50. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J Ferreira ST (2008) Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283, 9359 9368.
51. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, Hillen H, Gross G, Ebert U Bruehl C (2008) Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 28, 788 797.
52. Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, Sokolov Y, Hall JE Losche M (2008) Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophys J 95, 4845 4861.
53. Kawahara M Kuroda Y (2000) Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull 53, 389 397.
54. Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4, 49 60.
55. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128 1132.
56. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 31, 1153 1162.
57. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M Mucke L (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98, 12245 12250.
58. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O et al. (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 3, e3135.
59. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC Hyman BT (2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 116, 3339 3346.
60. Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T et al. (1997) An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389, 689 695.
61. Almeida CG, Takahashi RH Gouras GK (2006) Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 26, 4277 4288.
62. Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ Mook-Jung I (2005) Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech Ageing Dev 126, 1292 1299.
63. Tseng BP, Green KN, Chan JL, Blurton-Jones M LaFerla FM (2008) Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 29, 1607 1618.
64. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D'Andrea MR, Dinsmore S Nagele RG (2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223 236.
65. Nixon RA (2006) Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci 29, 528 535.
66. Yang AJ, Chandswangbhuvana D, Margol L Glabe CG (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52, 691 698.
67. Yuyama K, Yamamoto N Yanagisawa K (2008) Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation. J Neurochem 105, 217 224.
68. Sakono M, Zako T, Ueda H, Yohda M Maeda M (2008) Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. Febs J 275, 5982 5993.
69. Hartl FU Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295, 1852 1858.
70. Vainberg IE, Lewis SA, Rommelaere H, Ampe C, Vandekerckhove J, Klein HL Cowan NJ (1998) Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 93, 863 873.
71. Zako T, Iizuka R, Okochi M, Nomura T, Ueno T, Tadakuma H, Yohda M Funatsu T (2005) Facilitated release of substrate protein from prefoldin by chaperonin. FEBS Lett 579, 3718 3724.
72. Zako T, Murase Y, Iizuka R, Yoshida T, Kanzaki T, Ide N, Maeda M, Funatsu T Yohda M (2006) Localization of prefoldin interaction sites in the hyperthermophilic group II chaperonin and correlations between binding rate and protein transfer rate. J Mol Biol 364, 110 120.
73. Okochi M, Nomura T, Zako T, Arakawa T, Iizuka R, Ueda H, Funatsu T, Leroux M Yohda M (2004) Kinetics and binding sites for interaction of the prefoldin with a group II chaperonin: contiguous non-native substrate and chaperonin binding sites in the archaeal prefoldin. J Biol Chem 279, 31788 31795.
74. Macario AJ Conway de Macario E (2005) Sick chaperones, cellular stress, and disease. N Engl J Med 353, 1489 1501.
75. Muchowski PJ Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6, 11 22.
76. Powers ET, Morimoto RI, Dillin A, Kelly JW Balch WE (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78, 959 991.
77. Tam S, Geller R, Spiess C Frydman J (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8, 1155 1162.
78. Kitamura A, Kubota H, Pack CG, Matsumoto G, Hirayama S, Takahashi Y, Kimura H, Kinjo M, Morimoto RI Nagata K (2006) Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 8, 1163 1170.
79. Behrends C, Langer CA, Boteva R, Bottcher UM, Stemp MJ, Schaffar G, Rao BV, Giese A, Kretzschmar H, Siegers K et al. (2006) Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 23, 887 897.
80. Zhang Y, McLaughlin R, Goodyer C LeBlanc A (2002) Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156, 519 529.
81. Chui DH, Dobo E, Makifuchi T, Akiyama H, Kawakatsu S, Petit A, Checler F, Araki W, Takahashi K Tabira T (2001) Apoptotic neurons in Alzheimer's disease frequently show intracellular Abeta42 labeling. J Alzheimers Dis 3, 231 239.
82. Mousnier A, Kubat N, Massias-Simon A, Segeral E, Rain JC, Benarous R, Emiliani S Dargemont C (2007) von Hippel Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. Proc Natl Acad Sci USA 104, 13615 13620.
83. Sorgjerd K, Klingstedt T, Lindgren M, Kagedal K Hammarstrom P (2008) Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 377, 1072 1078.